UPDATE: Jefferies Downgrades Regeneron Pharmaceuticals to Hold on Limited Eylea Upside
Jefferies downgraded Regeneron Pharmaceuticals (NASDAQ: REGN) from Buy to Hold and maintained a $179.00 price target.
Jefferies noted, "We conducted another wAMD survey which predicts limited near/mid-term upside to Eylea sales over our ests and current valuation which already reflect anticipated growth. Notably, benefit from potential cmpding driven decline in Avastin use only modestly benefits Eylea. … Following REGN's Jan 8 pre- announcement of U.S. Eylea sales of $838M for Q4 2012 with FY2013 guidance of $1.2-$1.3B and based on our survey results, we increased our U.S. Eylea wAMD sales incrementally by 1-2% for 2013-17, modestly impacting the topline."
Regeneron Pharmaceuticals closed at $179.40 on Monday.
Latest Ratings for REGN
|Nov 2014||Bank of America||Maintains||Buy|
|Nov 2014||Brean Capital||Maintains||Buy|
|Nov 2014||Argus Research||Maintains||Buy|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.